Skip to main content
×
Search form
Home
About
Quality
Research Integrity
Policies & Procedures
Research & Innovation Strategy
Research Dashboard
Enterprise & Innovation
Nexus Innovation Centre
Enterprise Partnerships
Technology Transfer Office
Facilities & Equipment
Licencing Opportunities
Institutes & Centres
Bernal Institute
Health Research Institute
A-Z Research Centres
Expertise
Researcher Profiles
Find An Expert
Research Impact
Case Studies
Podcasts
President’s Research Excellence and Impact Awards
Contact
Covid-19
Student Gateway
Staff Gateway
A-Z Directory
Campus Phone Directory
Contact UL
Student Gateway
Staff Gateway
A-Z Directory
Campus Phone Directory
Contact UL
EN
GA
Follow us
The University of Limerick facebook
The University of Limerick Twitter
The University of Limerick Instagram
The University of Limerick on linked in
The University of Limerick on you-tube
The University of Limerick on Snap Chat
Home
About
Quality
Research Integrity
Policies & Procedures
Research & Innovation Strategy
Research Dashboard
Enterprise & Innovation
Nexus Innovation Centre
Enterprise Partnerships
Technology Transfer Office
Facilities & Equipment
Licencing Opportunities
Institutes & Centres
Bernal Institute
Health Research Institute
A-Z Research Centres
Expertise
Researcher Profiles
Find An Expert
Research Impact
Case Studies
Podcasts
President’s Research Excellence and Impact Awards
Contact
Covid-19
Search University of Limerick website
EN
GA
Search University of Limerick website
Toggle main navigation
Publication
Home
|
Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.
Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK
Journal of the American Society of Nephrology : JASN
(2001)
